We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

47 hedge funds and large institutions have $39.1M invested in Prelude Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more capital invested

Capital invested by funds: $22M → $39.1M (+$17.1M)

0.16% less ownership

Funds ownership: 48.15% → 47.99% (-0.16%)

6% less funds holding

Funds holding: 50 → 47 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

65% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 23

Holders
47
Holders Change
-3
Holders Change %
-6%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
23
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$901K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$60.4K
3
Prudential Financial
Prudential Financial
New Jersey
+$25.9K
4
SC
Shay Capital
New York
+$25.1K
5
HF
HRT Financial
New York
+$16.9K

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$171K
2
BlackRock
BlackRock
New York
-$168K
3
UBS Group
UBS Group
Switzerland
-$100K
4
Goldman Sachs
Goldman Sachs
New York
-$70K
5
Charles Schwab
Charles Schwab
California
-$65.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
26
HSBC Holdings
United Kingdom
$20.2K -$3.67K -3,664 -21%
AQR Capital Management
27
AQR Capital Management
Connecticut
$15.1K -$33.2K -33,147 -76%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$13.1K -$2.07K -2,068 -19%
Bank of America
29
Bank of America
North Carolina
$12.7K -$2.45K -2,445 -22%
Barclays
30
Barclays
United Kingdom
$12.5K +$110 +110 +1%
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$11K +$4.9K +4,885 +173%
TRCT
32
Tower Research Capital (TRC)
New York
$9.97K -$9.89K -9,872 -59%
Citigroup
33
Citigroup
New York
$8.6K +$1.26K +1,257 +27%
UBS Group
34
UBS Group
Switzerland
$6.01K -$100K -100,033 -96%
JP Morgan Chase
35
JP Morgan Chase
New York
$5.58K +$1.93K +1,930 +99%
SS
36
SBI Securities
Japan
$3.95K – – –
Nisa Investment Advisors
37
Nisa Investment Advisors
Missouri
$2.35K – – –
Carson Wealth (CWM LLC)
38
Carson Wealth (CWM LLC)
Nebraska
$2K -$2.8K -2,795 -70%
PNC Financial Services Group
39
PNC Financial Services Group
Pennsylvania
$1.69K -$9 -9 -0.8%
Group One Trading
40
Group One Trading
Illinois
$720 – – –
EWA
41
EverSource Wealth Advisors
Alabama
$128 -$59 -59 -40%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$75 – – –
Optiver Holding
43
Optiver Holding
Netherlands
$29 +$20 +20 New
IA
44
IFP Advisors
Florida
$26 -$16 -16 -47%
EP
45
Essential Partners
California
$24 -$70 -70 -80%
AAP
46
Arax Advisory Partners
Colorado
$22 +$15 +15 New
CF
47
Cantor Fitzgerald
New York
– -$171K -211,859 Closed
Charles Schwab
48
Charles Schwab
California
– -$65.4K -80,845 Closed
YIH
49
Y-Intercept (HK)
Hong Kong
– -$38.7K -47,788 Closed
Marshall Wace
50
Marshall Wace
United Kingdom
– -$33.8K -41,747 Closed
1
2
3

PRLD Hedge Fund Activity: Q3 2025 in Review

47 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2025, worth a combined $39.1M — up 78% from $22M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PRLD and 5 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 8 added.

The largest buyer was Millennium Management, adding an estimated $901K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $171K sold.

  • 47 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2025, down from 50 in Q2 2025.
  • Funds reported $39.1M of Prelude Therapeutics stock for Q3 2025, up 78% quarter-over-quarter.
  • 5 funds opened new Prelude Therapeutics positions in Q3 2025 and 8 closed out, a net change of -3 holders.
  • The largest Prelude Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $901K added.
  • The largest Prelude Therapeutics seller in Q3 2025 was Cantor Fitzgerald, an estimated $171K sold.

Based on aggregated 13F filings for Q3 2025.